All In Biotech

Drug Trial Radar · NCT07220577

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

34

Actual

Start

Nov 10, 2025

Primary completion

May 17, 2027

Study completion Sep 6, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • GIA632Drug

    Active treatment arm

  • PlaceboOther

    Placebo treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IGA response at Week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baselineTime frame: Baseline, Week 16

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • Ctr for Dermatology Clinical Res

    Fremont, California

  • Aesthetics Skin Care Dermatologic Surgery

    Rockville, Maryland

  • Care Access Hoboken

    Hoboken, New Jersey

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Québec, Quebec, Canada

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Ostrava, Poruba, Czechia

  • Novartis Investigative Site

    Antony, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Martigues, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia

  • Novartis Investigative Site

    Ipoh, Perak, Malaysia

  • Novartis Investigative Site

    George Town, Pulau Pinang, Malaysia

  • Novartis Investigative Site

    Kota Kinabalu, Sabah, Malaysia

  • Novartis Investigative Site

    Gdansk, Poland

  • Novartis Investigative Site

    Torun, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.